Benefits of Herceptin in subsequent lines of therapy for metastatic breast cancer

Herceptin has been shown to deliver high response rates in further lines of MBC.

H0649g 

In the multicentre H0649g study, patients who had progressed after at least one line of chemotherapy in metastatic disease achieved an objective response rate of 15% with Herceptin monotherapy.¹

Table 3.4 Efficacy of Herceptin monotherapy in second-line metastatic breast cancer (H0649g).¹

Herceptin treatment beyond disease progression may also improve overall survival relative to initial Herceptin-based therapy only.

H0649g trial

A multicentre, open-label, single-arm trial of Herceptin as second-line monotherapy.